Medpace Holdings (MEDP) Peer Comparison

$622.11

$6.17 (1.00%)

As on 29-Sep-2026 16:00EDT

Market cap

$17,274 Mln

Revenue (TTM)

$2,782 Mln

P/E Ratio

36.4

P/B Ratio

39.7

Div. Yield

0 %

Edit

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	17,274	14,841	14,411	12,927	11,935
Revenue ($ Mln)	2,782	1,054	2,436	1,664	1,284
Net Profit ($ Mln)	491.50	755.85	860.62	413.60	-325.10
Net Margin (%)	17.67	71.69	35.33	24.86	-25.32
RoE (%)	110.09	--	42.98	430.03	-57.72
Price to Earnings	36.40	17.63	18.29	33.40	--
Price-To-Book	39.70	8.91	7.82	88.91	22.63

Income Statement ($ Mln)

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	2,782.29	1,054.37	2,435.92	1,663.74	1,283.94
Cost of Revenue	1,982.07	103.47	85.67	363.07	109.42
Gross Profit	760.62	588.53	2,236.43	1,091.18	902.26
Operating Expenses	216.81	841.45	1,378.74	356.18	1,497.13
Operating Profit (EBIT)	583.40	109.45	971.51	944.49	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	598.92	101.11	1,035.47	583.34	-325.10
Provision for Tax	107.42	-654.74	174.84	169.74	0.00
Profit after Tax (Net Income)	491.50	755.85	860.62	413.60	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	433.86	1,435.90	1,843.76	143.54	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	187.89	384.48	288.55	2,089.43	346.72
Current Liabilities	1,435.43	464.70	361.93	344.44	374.20
Total Liabilities	1,975.47	1,302.02	2,844.42	2,525.32	1,259.59

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	1,006.90	895.24	1,243.41	1,644.38	45.47
Current Assets	1,050.29	1,389.84	1,250.82	933.02	1,199.18
Total Assets	1,975.47	1,302.02	2,844.42	2,525.32	1,259.59
Total Debt*	120.10	449.89	165.93	2,146.65	347.75
Net Current Assets	-385.14	925.52	888.90	588.59	824.98

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	713.22	51.77	884.27	651.56	-189.55
Cash Flow from Investing Activities	-31.14	-8.15	350.44	-545.81	32.32
Cash from Financing Activities	-860.39	34.89	-969.59	-85.17	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	53.56	-30.01	32.82	15.61	-31.49
ROE (%)	110.09	163.18	42.98	430.03	-57.72
ROA (%)	15.64	31.68	29.32	16.19	-22.97
EBIT Margin (%)	21.13	5.73	31.04	36.28	-18.97
Net Margin (%)	17.67	71.69	35.33	24.86	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	24.67	114.85	9.23	41.15	149.04
EBIT Growth (%)	18.70	136.39	-3.99	-14.99	9.16
Net Profit Growth (%)	17.50	378.76	42.89	-25.78	-15.32
EPS Growth (%)	26.84	353.27	50.42	-23.48	-0.64
Book Value Growth (%)	164.02	816.12	-0.70	-55.81	-42.66

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	36.06	-59.76	15.79	24.99	-45.32
Price / Book Value	35.44	-80.42	5.72	162.23	21.68
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	28.08	-121.54	12.44	17.31	-47.02
Market Cap ($ Cr)	--	--	--	--	--

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.27	0.00	13.50	0.65
Short term debt to equity ratio	0.00	0.05	0.00	1.46	0.00
Current Ratio	0.73	2.99	3.46	2.71	3.20
Quick Ratio	0.73	2.32	3.38	2.31	2.94
Interest Coverage	--	1.62	--	29.73	-9.32

	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Halozyme Therapeutics (HALO)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	15.88	21.25	13.74	27.40	14.98
Asset Turnover	0.89	0.44	0.83	0.65	0.91
Receivable days	50.42	85.52	43.48	98.04	35.88
Inventory Days	--	1,056.70	96.17	190.34	354.23
Payable days	6.26	331.01	147.97	18.62	300.79
Cash Conversion Cycle	--	811.21	-8.32	269.75	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.